Search results for "Azole"

showing 10 items of 2392 documents

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Interventionelle ERCP bei Patienten mit Cholestase: Häufigkeit und Antibiotikaresistenz der biliären Keimbesiedlung

2001

Interventional ERCP in patients with cholestasis. Degree of biliary bacterial colonization and antibiotic resistance. Biliary obstruction together with bacterial colonization of the bile duct may lead to development of acute cholangitis. The aim of our prospective study was to investigate the presence and degree of biliary bacterial colonization by means of bile aspiration during ERCP in patients with biliary obstruction. Furthermore, we evaluated antibiotic therapy regimens, which would cover the bacterial species obtained by ERCP and subsequent culture in each patient. In addition, analysis of risk factors was performed that would predispose to the development of cholangitis.80 patients w…

medicine.medical_specialtyBile ductbusiness.industryGastroenterologymedicine.diseasedigestive systemGastroenterologydigestive system diseasesMetronidazolemedicine.anatomical_structureCholestasisLevofloxacinBacteremiaInternal medicinemedicineCeftriaxoneAnaerobic bacteriabusinessmedicine.drugAntibacterial agentZeitschrift für Gastroenterologie
researchProduct

Improving opportunities for effective management of gastro-oesophageal reflux disease

2002

The recent introduction of proton pump inhibitors has extraordinarily improved the therapeutic approach to gastro-oesophageal reflux disease. The concept of decreasing gastric acid secretion and increasing the pH in the lower oesophagus has been demonstrated to be therapeutically effective and the higher the level of pH achieved, the better the results. In spite of the evident efficacy of these molecules, there are still many patients who will continue to have symptoms despite medical treatment. Proton pump inhibitors suppress gastric acidity, but this effect shows a remarkable interindividual variation depending on different reasons. Thus, it is still possible to optimise medical therapy f…

medicine.medical_specialtyBiological AvailabilityDiseaseGastroenterologyEsomeprazoleTherapeutic approachIsomerismInternal medicineEsophagitisHumansMedicineOmeprazoleHepatologybusiness.industrydigestive oral and skin physiologyGastroenterologyRefluxEsomeprazoleProton Pump InhibitorsHydrogen-Ion ConcentrationAnti-Ulcer Agentsdigestive system diseasesClinical trialTreatment OutcomeTolerabilityGastric MucosaGastroesophageal RefluxGastric acidbusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats

2017

Background The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats. Material and Methods 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/kg ZOL intravenously once a week for 6 weeks. The rats from CTRL and OVX groups were injected with 0.9% NaCl. Implants were placed in the left tibia. Afte…

medicine.medical_specialtyBone densityOvariectomyDentistryZoledronic AcidOsseointegration03 medical and health sciences0302 clinical medicineAbsorptiometry PhotonBone DensityOsseointegrationInternal medicineMedicineAnalysis softwareAnimalsTibiaRats WistarGeneral DentistryBone mineralDental ImplantsBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchSham surgeryImidazoles030206 dentistry:CIENCIAS MÉDICAS [UNESCO]RatsZoledronic acidEndocrinologyOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOvariectomized ratSurgeryFemaleOral Surgerybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group fo…

2000

Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

medicine.medical_specialtyBone marrow transplantPremedicationAntibodies ProtozoanBlood DonorsOpportunistic InfectionsImmunocompromised HostSeroepidemiologic StudiesInternal medicineTrimethoprim Sulfamethoxazole Drug CombinationEpidemiologymedicineAnimalsHumansTransplantation HomologousTransplantationMarrow transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologymedicine.diseaseToxoplasmosisTransplantationHaematopoiesissurgical procedures operativeImmunologybusinessToxoplasmaDisease transmissionToxoplasmosisBone Marrow Transplantation
researchProduct

Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder

2013

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 d…

medicine.medical_specialtyCYP2D6Venlafaxine HydrochlorideVenlafaxineCYP2C19Severity of Illness IndexGastroenterologyAnti-Infective AgentsInternal medicineTremorTrimethoprim Sulfamethoxazole Drug CombinationHumansMedicineDrug InteractionsPharmacology (medical)PsychiatryCYP2C9PharmacologyDepressive Disorder MajorCYP3A4business.industryVenlafaxine HydrochlorideMiddle AgedCyclohexanolsmedicine.diseaseTrimethoprimCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Major depressive disorderFemaleAryl Hydrocarbon HydroxylasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation.

medicine.medical_specialtyCancer ResearchHematologyCetuximabintegumentary systembusiness.industryGeneral MedicineMinocyclineRashDermatologydigestive system diseasesSurgeryMetronidazoleOncologyInternal medicineMonoclonalmedicinePrednisolonemedicine.symptomAntibiotic prophylaxisbusinessneoplasmsmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the …

2013

Kast, Richard E. et al.

medicine.medical_specialtyCaptoprilTel avivMorpholinesArtesunateReviewGluconatesAngiotensinQuality of lifeAuranofinSertralineAntineoplastic Combined Chemotherapy ProtocolsDisulfiramTemozolomidemedicineRecurrent diseaseHumansIn patientNelfinavirTemozolomideBrain Neoplasmsbusiness.industrySuccinatesNeurokininCytotoxic chemotherapyUniversity hospitalmedicine.diseaseArtemisininsSurgeryDacarbazineKetoconazoleOncologyangiotensin aprepitant artesunate auranofin captopril cytokines disulfiram glioblastoma ketoconazole nelfinavir neurokinin sertraline temozolomideFamily medicineCytokinesNeoplasm Recurrence LocalGlioblastomabusinessAprepitantGlioblastomamedicine.drugOncotarget
researchProduct

Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine.

1996

Abstract 1. The effects of SR 48692 on neurotensin (NT)-induced mechanical responses were investigated in rat duodenum and proximal colon by use of isometric, isovolumic preparations. 2. SR 48692 inhibited the relaxant responses to NT in duodenal circular and longitudinal muscle. It also antagonized the NT-induced contractile effects in duodenal circular muscle and in proximal colon (both muscular layers). 3. From Schild analysis and pA2 value for SR 48692 was 8.2 in tissues where NT induced relaxant effects and 7.5 in tissues where NT induced contractile effects and the slope of the regression line was not significantly different from unity, indicating competitive antagonism. 4. SR 48692 d…

medicine.medical_specialtyCarbacholColonDuodenumMuscle RelaxationNeuropeptideSubstance PBiologyPeptide hormoneIn Vitro Techniqueschemistry.chemical_compoundNorepinephrineInternal medicineIsometric ContractionmedicineAnimalsReceptors NeurotensinVasoconstrictor AgentsRats WistarReceptorNeurotensinPharmacologyMuscle SmoothRatsMuscle relaxationmedicine.anatomical_structureEndocrinologychemistryDuodenumQuinolinesPyrazolesmedicine.drugNeurotensinResearch ArticleBritish journal of pharmacology
researchProduct